Olsen James P, Baldwin Scott, Houts Arthur C
Department of Psychology, University of Memphis, Tennessee, USA.
Oncol Nurs Forum. 2011 May;38(3):360-7. doi: 10.1188/11.ONF.360-367.
PURPOSE/OBJECTIVES: To provide an initial evaluation of the psychometric properties of the Patient Care Monitor 1.0 Revised-Neutropenia Index (PCM-N), a symptom-based assessment tool designed to measure health-related quality-of-life (HRQOL) changes associated with chemotherapy-induced neutropenia.
Known-groups methodology and self-report instrument validation.
A large community oncology practice in Memphis, TN.
424 patients with cancer in four samples.
All patients in the first three samples were assessed at baseline of chemotherapy administration and at a point analogous to midcycle. The fourth sample underwent a cross-sectional evaluation of the ability of the PCM-N to distinguish patients with febrile neutropenia, severe afebrile neutropenia, and no neutropenia.
PCM-N score, grade of neutropenia, and febrile status.
Internal consistency reliability and factor analysis supported the single additive scale structure of the 13 items of the PCM-N. The PCM-N demonstrated good known-groups validity and was able to distinguish patients with grades 3-4 neutropenia from those with grades 0-2. The tool also was able to distinguish patients with febrile neutropenia, severe afebrile neutropenia, and no neutropenia. Receiver operating characteristic analyses provided a psychometrically based threshold score.
The PCM-N is a reliable and valid instrument sensitive to changes in HRQOL associated with moderate-to-severe chemotherapy-induced neutropenia.
Nurses can use the PCM-N as a rapid and cost-effective tool for monitoring symptoms of neutropenia in patients with cancer.
目的/目标:对患者护理监测器1.0修订版 - 中性粒细胞减少指数(PCM - N)的心理测量特性进行初步评估,这是一种基于症状的评估工具,旨在测量与化疗引起的中性粒细胞减少相关的健康相关生活质量(HRQOL)变化。
已知组方法和自我报告工具验证。
田纳西州孟菲斯的一个大型社区肿瘤学实践机构。
四个样本中的424名癌症患者。
前三个样本中的所有患者在化疗给药基线和类似于化疗周期中期的时间点进行评估。第四个样本对PCM - N区分发热性中性粒细胞减少、严重非发热性中性粒细胞减少和无中性粒细胞减少患者的能力进行了横断面评估。
PCM - N评分、中性粒细胞减少等级和发热状态。
内部一致性信度和因子分析支持PCM - N的13个项目的单一累加量表结构。PCM - N显示出良好的已知组效度,能够区分3 - 4级中性粒细胞减少患者和0 - 2级患者。该工具还能够区分发热性中性粒细胞减少、严重非发热性中性粒细胞减少和无中性粒细胞减少的患者。受试者工作特征分析提供了一个基于心理测量的阈值分数。
PCM - N是一种可靠且有效的工具,对与中度至重度化疗引起的中性粒细胞减少相关的HRQOL变化敏感。
护士可以将PCM - N作为一种快速且经济高效的工具,用于监测癌症患者的中性粒细胞减少症状。